Intercell AG was a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology in Vienna.It employs 400 people in Austria, Scotland and the United States.It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.The most important projects of Intercell are: Vaccine against Japanese encephalitis Therapeutic vaccine against hepatitis C Antigen identification program and adjuvant technologies. Vaccine Enhancement Patch to improve prevention against pandemic influenza ↑ 1.0 1.1 1.2 1.3 1.4 1.5 ↑ ↑ ↑ ↑ ↑ ↑ ↑ Wikipedia.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2011.1.4-4 | Award Amount: 40.88M | Year: 2011
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise. A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the Sclavo Vaccines Association (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.06M | Year: 2012
Vaccines are the most cost-effective health interventions available (WHO). The impact of vaccination on the health of the worlds population cannot be overstressed. Vaccinolgy is the multidisciplinary discipline of developing vaccine interventions it combines knowledge from basic sciences, medical sciences, public health and social sciences. Ideally a vaccinologists would be able to have a general overview of all disciplines involved but at the same time be able to zoom in on its own discipline. There is hardly any formal training to become a vaccinologist in the world and none such training exists at a PhD level in Europe. The need for a program to train vaccinologists is apparent and recognised . The vaccine industry is a largely European based industry. Investing in the future of this industry by training the next generation vaccinologists will boost Europeans economy will provide high quality employment and will sustain Europeans competitiveness. Clearly there are public health and economic reasons to invest in a training program training the European vaccinologists of the future.
Intercell | Date: 2013-01-31
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.
Intercell | Date: 2013-03-12
The present invention relates to a new use of a vaccine comprising a fusion protein that comprises the Pseudomonas aeruginosa outer membrane protein I (OprI or OMPI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF or OMPF), as well as to a new use of a monoclonal or polyclonal antibody against this fusion protein or a pharmaceutical composition thereof.
Intercell | Date: 2013-01-16
The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R_(1)-XZXZ_(N)XZX-R_(2), whereby
Intercell | Date: 2013-01-09
Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.
Intercell | Date: 2013-03-06
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2 deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2 deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5 or 3 ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
Intercell | Date: 2013-08-15
The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S. pyogenes infection; a method for identifying a ligand capable of binding to said peptide; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.
Intercell | Date: 2013-04-17
The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
Intercell | Date: 2013-05-06
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.